Klinik und Hochschulambulanz für Neurologie Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin Berlin Germany.
J Am Heart Assoc. 2023 Feb 7;12(3):e8189. doi: 10.1161/JAHA.122.027284. Epub 2023 Feb 3.
Background Cerebral microbleeds (CMBs) are increasingly recognized as "covert" brain lesions indicating increased risk of future neurological events. However, data on CMBs in patients undergoing catheter-based structural heart interventions are scarce. Therefore, we assessed occurrence and predictors of new CMBs in patients undergoing catheter-based left atrial appendage closure and percutaneous mitral valve repair using the MitraClip System. Methods and Results We conducted an exploratory analysis using data derived from 2 prospective, observational studies. Eligible patients underwent cerebral magnetic resonance imaging (3 Tesla) examinations and cognitive tests (using the Montreal Cognitive Assessment) before and after catheter-based left atrial appendage closure and percutaneous mitral valve repair. Forty-seven patients (53% men; median age, 77 years) were included. New CMBs occurred in 17 of 47 patients (36%) following catheter-based structural heart interventions. Occurrences of new CMBs did not differ significantly between patients undergoing catheter-based left atrial appendage closure and percutaneous mitral valve repair (7/25 versus 10/22; =0.348). In univariable analysis, longer procedure time was significantly associated with new CMBs. Adjustment for heparin attenuated this association (adjusted odds ratio [per 30 minutes]: 1.77 [95% CI, 0.92-3.83]; =0.090). Conclusions New CMBs occur in approximately one-third of patients after catheter-based left atrial appendage closure and percutaneous mitral valve repair using the MitraClip System. Our data suggest that longer duration of the procedure may be a risk factor for new CMBs. Future studies in larger populations are needed to further investigate their clinical relevance. Clinical Trial Registration German Clinical Trials Register: DRKS00010300 (https://drks.de/search/en/trial/DRKS00010300); ClinicalTrials.gov : NCT03104556 (https://clinicaltrials.gov/ct2/show/NCT03104556?term=NCT03104556&draw=2&rank=1).
脑微出血(CMB)越来越被认为是“隐匿性”脑损伤,提示未来发生神经事件的风险增加。然而,关于接受经导管结构性心脏介入治疗的患者的 CMB 数据很少。因此,我们评估了接受经导管左心耳封堵术和经皮二尖瓣修复术(使用 MitraClip 系统)的患者中新 CMB 的发生情况和预测因素。
我们使用来自 2 项前瞻性观察性研究的数据进行了探索性分析。合格的患者在接受经导管左心耳封堵术和经皮二尖瓣修复术之前和之后接受了脑磁共振成像(3 Tesla)检查和认知测试(使用蒙特利尔认知评估)。47 名患者(53%为男性;中位年龄为 77 岁)被纳入研究。在接受经导管结构性心脏介入治疗后,47 名患者中有 17 名(36%)发生了新的 CMB。接受经导管左心耳封堵术和经皮二尖瓣修复术的患者中新 CMB 的发生率无显著差异(7/25 与 10/22;=0.348)。单变量分析显示,手术时间较长与新 CMB 显著相关。调整肝素后,这种关联减弱(调整后的比值比[每 30 分钟]:1.77[95%置信区间,0.92-3.83];=0.090)。
大约三分之一的接受经导管左心耳封堵术和经皮二尖瓣修复术(使用 MitraClip 系统)的患者在手术后会出现新的 CMB。我们的数据表明,手术时间较长可能是新 CMB 的危险因素。需要在更大的人群中进行进一步的研究,以进一步探讨其临床意义。
德国临床试验注册处:DRKS00010300(https://drks.de/search/en/trial/DRKS00010300);ClinicalTrials.gov:NCT03104556(https://clinicaltrials.gov/ct2/show/NCT03104556?term=NCT03104556&draw=2&rank=1)。